These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26336595)

  • 41. Riociguat for the treatment of pulmonary arterial hypertension.
    Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
    N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of pulmonary arterial hypertension in children.
    Gorenflo M; Ziesenitz VC
    Cardiovasc Diagn Ther; 2021 Aug; 11(4):1144-1159. PubMed ID: 34527540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on pulmonary arterial hypertension pharmacotherapy.
    Velayati A; Valerio MG; Shen M; Tariq S; Lanier GM; Aronow WS
    Postgrad Med; 2016 Jun; 128(5):460-73. PubMed ID: 27232660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacotherapy for pulmonary arterial hypertension.
    Parikh V; Bhardwaj A; Nair A
    J Thorac Dis; 2019 Sep; 11(Suppl 14):S1767-S1781. PubMed ID: 31632754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy.
    Ataya A; Cope J; Alnuaimat H
    J Clin Med; 2016 Dec; 5(12):. PubMed ID: 27929408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.
    Kim JS; McSweeney J; Lee J; Ivy D
    Pediatr Crit Care Med; 2016 Mar; 17(3 Suppl 1):S89-100. PubMed ID: 26945333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension.
    Hellawell JL; Bhattacharya S; Farber HW
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1445-53. PubMed ID: 25204984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.
    Madonna R; Cocco N; De Caterina R
    Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathways in pulmonary arterial hypertension: the future is here.
    Sitbon O; Morrell N
    Eur Respir Rev; 2012 Dec; 21(126):321-7. PubMed ID: 23204120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension.
    Mirza S; Foley RJ
    Clin Med Insights Circ Respir Pulm Med; 2012; 6():41-50. PubMed ID: 22872790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pulmonary arterial hypertension: on the way to a manageable disease.
    Mucke HA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):957-62. PubMed ID: 18729002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].
    Sommer N; Richter MJ; Tello K; Grimminger F; Seeger W; Ghofrani HA; Gall H
    Internist (Berl); 2017 Sep; 58(9):937-957. PubMed ID: 28819824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.
    Steriade A; Seferian A; Jaïs X; Savale L; Jutant EM; Parent F; Sitbon O; Humbert M; Simonneau G; Montani D
    Ther Adv Respir Dis; 2014 Jun; 8(3):84-92. PubMed ID: 24728960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension.
    Kuwana M; Abe K; Kinoshita H; Matsubara H; Minatsuki S; Murohara T; Sakao S; Shirai Y; Tahara N; Tsujino I; Takahashi K; Kanda S; Ogo T
    Pulm Circ; 2023 Jan; 13(1):e12198. PubMed ID: 36788940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
    Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
    Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhaled treprostinil and pulmonary arterial hypertension.
    Nadler ST; Edelman JD
    Vasc Health Risk Manag; 2010 Dec; 6():1115-24. PubMed ID: 21191432
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.